|| Checking for direct PDF access through Ovid
A 76-year-old man with castration-resistant prostate cancer and widespread skeletal metastases underwent 2 cycles of 177Lu–prostate-specific membrane antigen (PSMA) 617 therapy in our department. Whole-body 177Lu-PSMA scan after the first cycle showed diffuse skeletal PSMA-avid lesions, whereas no PSMA uptake was evident in the kidneys with minimal PSMA uptake by salivary glands (super scan). After 6 weeks, he received the second dose of 177Lu-PSMA and whole-body scan after the treatment showed remarkable resolution of skeletal metastases and normal PSMA uptake by the kidneys and salivary glands. To our best knowledge, this is the first case report of 177Lu-PSMA super scan.